Mitigating treatment lag for infantile epileptic spasms syndrome in low‐ and middle‐income countries: Key recommendations from the South Asia allied IESS Research Group

This is the authors' abstract. We don't add key points for this paper.

J.H.C. has acted as an investigator for studies with GW Pharma/Jazz Pharmaceuticals, Zogenix/UCB Pharma, Vitaflo, Stoke Therapeutics, and Ultragenyx. She has been a speaker and on advisory boards for Jazz Pharmaceuticals, UCB, Biocodex, and Nutricia; all remuneration has been paid to her department. She holds an endowed chair at UCL Great Ormond Street Institute of Child Health; she holds grants from National Institute of Health Research (NIHR), EPSRC, GOSH Charity, ERUK, the Waterloo Foundation, and the NIHR Biomedical Research Centre at Great Ormond Street Hospital. J.W. (Jo Wilmshurst) is an associate editor for Epilepsia, chief editor of the Pediatric Neurology subsection of Frontiers in Neurology, and on the South African national advisory board for Sanofi, Novartis, and Roche. The remaining authors have no conflicts of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. All important data related to the article are given within the article. Table S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.